TR201900369T4 - The modulation of solubility, stability, absorption, metabolism and pharmacokinetic profile of lipophilic drugs by sterols. - Google Patents
The modulation of solubility, stability, absorption, metabolism and pharmacokinetic profile of lipophilic drugs by sterols. Download PDFInfo
- Publication number
- TR201900369T4 TR201900369T4 TR2019/00369T TR201900369T TR201900369T4 TR 201900369 T4 TR201900369 T4 TR 201900369T4 TR 2019/00369 T TR2019/00369 T TR 2019/00369T TR 201900369 T TR201900369 T TR 201900369T TR 201900369 T4 TR201900369 T4 TR 201900369T4
- Authority
- TR
- Turkey
- Prior art keywords
- therapeutic agent
- sterols
- metabolism
- absorption
- stability
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 229930182558 Sterol Natural products 0.000 title abstract 5
- 235000003702 sterols Nutrition 0.000 title abstract 5
- 150000003432 sterols Chemical class 0.000 title abstract 3
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 230000004060 metabolic process Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 229940124597 therapeutic agent Drugs 0.000 abstract 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 sterol esters Chemical class 0.000 abstract 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract 1
- 229960003473 androstanolone Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 150000003515 testosterones Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Sterollerle ve/veya sterol esterleriyle formülasyon yoluyla bir lipofilik terapötik ajanın çözünürlüğünün, stabilitesinin, absorpsiyonunun, metabolizmasının ve/veya farmakokinetik profilinin gelişmesini sağlayarak, böyle bir terapötik ajana ihtiyaç duyan bir deneğe uygulanan terapötik ajanın daha yüksek biyoyararlanıma sahip olmasını sağlayan bir ilaç dağıtım formülasyonudur. Formülasyon bir terapötik ajan ve bir sterol veya sterol esteri ihtiva eder ve isteğe bağlı olarak ayrıca bir çözünürleştirici ve/veya bir geliştirici ajan ihtiva edebilir. Ayrıca, formülasyonları ihtiva eden farmasötik bileşimler, formülasyonların ve farmasötik bileşimlerin hazırlanması için yöntemler ve kullanılması için yöntemler de tarif edilmektedir. Buluşun formülasyonları, terapötik ajan testosteron veya testosteron esterleri içerdiğinde dihidrotestosteron sentezini minimize edecek şekilde konstitüe edilebilir.It is a drug delivery formulation that provides improved solubility, stability, absorption, metabolism and / or pharmacokinetic profile of a lipophilic therapeutic agent through formulation with sterols and / or sterol esters, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such a therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and optionally may also contain a solubilizer and / or a enhancing agent. Also described are pharmaceutical compositions containing formulations, methods for preparing formulations and pharmaceutical compositions, and methods for using them. The formulations of the invention can be constituted so as to minimize dihydrotestosterone synthesis when the therapeutic agent contains testosterone or testosterone esters.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061291769P | 2010-12-31 | 2010-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900369T4 true TR201900369T4 (en) | 2019-02-21 |
Family
ID=67956163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00369T TR201900369T4 (en) | 2010-12-31 | 2011-12-31 | The modulation of solubility, stability, absorption, metabolism and pharmacokinetic profile of lipophilic drugs by sterols. |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201900369T4 (en) |
-
2011
- 2011-12-31 TR TR2019/00369T patent/TR201900369T4/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011082384A3 (en) | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | |
| NZ631833A (en) | Emulsion formulations | |
| CY1119616T1 (en) | HUMAN ANTI-DUMP DRUG CONSUMPTION AGAINST TISSUE | |
| CY1123649T1 (en) | IMIDAZOLINE DERIVATIVES, METHODS OF THEIR PREPARATION AND THEIR APPLICATIONS IN MEDICINE | |
| SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
| WO2011063952A8 (en) | Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration | |
| MY175800A (en) | Combination treatment of cancer | |
| BR112014030714A2 (en) | ionizable lipid compound, compositions, drug carrier, pharmaceutical formulation and method of delivery of a drug | |
| MX2013002975A (en) | Estrogen receptor modulators and uses thereof. | |
| MX2011011514A (en) | Formulations of cannabidiol and methods of using the same. | |
| MX2011002065A (en) | Micronised progesterone pharmaceutical composition and uses thereof. | |
| BR112012030653A2 (en) | storage stable, substantially anhydrous topical aerosol composition and pressurized container | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| IL218071A0 (en) | Novel pharmaceutical formulations to prevent the misuse of medicinal drugs | |
| IL226398B2 (en) | Pharmaceutical formulations containing corticosteroids for topical administration | |
| IN2014DN00277A (en) | ||
| WO2011019326A3 (en) | Solubility and stability enchancing pharmaceutical formulation | |
| IN2014CN03214A (en) | ||
| PH12015502556A1 (en) | Modified release formulation | |
| IN2015DN02999A (en) | ||
| EP2682129A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous | |
| MX2016007741A (en) | Pharmaceutical combined preparation containing hmg-coa reductase inhibitor and cholesterol absorption inhibitor. | |
| EA032913B1 (en) | Formulations of pyrimidinedione derivative compounds | |
| TR201900369T4 (en) | The modulation of solubility, stability, absorption, metabolism and pharmacokinetic profile of lipophilic drugs by sterols. | |
| WO2011128634A3 (en) | Over the counter pharmaceutical compositions |